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ABSTRACT
Engineering and Evaluation of Reconstituted HDL nanoparticles to target
Tumor-Associated Macrophages.
MAY 2022

AISHWARYA MENON,

B.TECH., INSTITUTE OF CHEMICAL TECHNOLOGY

M.S.ChE., UNIVERSITY OF MASSACHUSETTS AMHERST

Directed by: Ashish Kulkarni
Conventional cancer therapies such as chemotherapy and radiation often lead to severe
side effects since they are unable to specifically target the tumor. Additionally, they do
not guarantee the prevention of metastasis or recurrence. Recent developments on smallmolecule inhibitors, such as kinase inhibitors that target cellular pathways
characteristically upregulated in cancer cells, show promise. However, significant
challenges such as tolerance and mutations causing drug resistance need to be overcome.
Immunotherapy, wherein the host's immune system is leveraged to recognize and target
cancer cells, is a better alternative that shows reduced toxicity. Macrophages are an
attractive target for immunotherapy seeing as they constitute 50% of the infiltrating
leukocytes in the tumor microenvironment. Their plastic nature allows them to be
modulated from pro-tumor to anti-tumor phenotype. Although, it does not work for
everyone, necessitating a need to monitor response to medication at earlier time points.
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In this thesis, I have designed an HDL mimicking nanoparticle system to target tumor
associated M2 macrophages through the SRB1 receptor. The nanoparticle was optimized
for better stability, better loading of the targeting peptide, and the drug as well. It was
used to deliver a CSF1R inhibitor drug to successfully repolarize pro-tumor M2
macrophages to anti-tumor M1 phenotype. In addition to that, it was also used to deliver
an Arginase-responsive probe that only fluoresces when engulfed by arginase-producing
M2 macrophages, differentiating them from arginase non-producing M1 phenotype.
Through this study, the SRB1 receptor was successfully targeted to effectively deliver
small molecules. This can be used to target and modulate tumor-associated macrophages.
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CHAPTER I
INTRODUCTION
1.1 Motivation
According to the WHO, cancer is listed as one of the leading causes of premature
death. The American Cancer Society projects 1.93 million new cases and over 600,000
deaths related to cancer in 2021. Cancers of the prostate, breast, lung, and colon are
expected to be the most common (FIG 1). The most common factor contributing to
cancer deaths is metastasis, which is when the primary tumor spreads to other organs and
body parts. [12].
Conventional treatments for cancer, including radiation, chemotherapy, and surgery,
often lead to severe side effects. Both radiation and chemotherapy, though possessing
high tumoricidal capacity, do not specifically target cancers. Therefore, they tend to be
severely toxic to other cells and organs. Side effects can range from hair loss, nausea,
diarrhea to heart failure, central nervous system toxicities, hypertension etc. [1] Surgery
is only possible depending upon the accessibility of the cancerous mass and does not
guarantee prevention of metastasis or recurrence. [2]
Targeted therapies, on the other hand, target cellular pathways that are characteristic of
cancer cells, thereby leaving healthy cells unharmed. Small molecule inhibitors such as
kinase inhibitor imatinib [3], EGFR inhibitor Gefitinib [4] etc. and antibodies such as
VEGF targeting Bevacizamab [5] are some examples of FDA approved targeted
treatments. However, there are several challenges that need to be overcome such as
mutations leading drug resistance and tolerance. [6]
1

It has been well observed that the immune system plays a critical role in suppressing or
promoting tumors. [7] Several immune check point inhibitors such as anti CTLA-4 drug
ipilimumab [8] and anti PD/PDL1 drug pembrolizumab [9] have been approved by the
FDA against advanced melanoma, non-small cell lung cancer, renal cell carcinoma and
Hodgkin’s lymphoma. However, while immunotherapy is an attractive option, not all
patients respond equally to it. Currently, only 20% to 40% of recipients respond
positively [10]. Moreover, conventional imaging techniques like PET lack the sensitivity
and specificity for early response assessment. [11] Therefore, there is a need to have an
imaging system that can detect early response to therapies to better predict its efficacy.

Figure 1: Estimated statistics for new cancer cases and deaths in the United States in 2021, Cancer
Therapy Advisor, 2021

1.2 Role of the Immune System in Cancer
A growing solid tumor acquires several biological characteristics that allow it to
grow unhindered. They hijack cell regulation signals through mutations or inhibition of
suppressors and proliferate endlessly. [13] Angiogenesis, or the process of sprouting new
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blood vessels from existing ones, ensures they have a supply of nutrients and oxygen, as
well as channel to dispose of metabolic wastes and carbon dioxide. [14] Mutations
leading to loss of adhesion molecules such as E-cadherin allows them to invade and
spread to distant organs. [15] Additionally, they escape recognition by immune cells by
upregulating expression of markers such as CD 47, PD L1 etc. that prevent the immune
cells from killing them. [16]
They do not achieve this alone but are helped by stromal cells that are recruited into the
tumor, which include immune cells. Macrophages are a major component among them.
In this context, they are referred to as Tumor-Associated Macrophages or TAMs.
Macrophages can change their phenotype in response to chemical messengers called
cytokines that are released by tumor and stromal cells. [17] In the presence of TLR
agonists such as LPS and cytokines such as INF γ, macrophages get activated to a proinflammatory phenotype known as the classically activated ‘M1’ state, characterized by
an upregulation of CD80 and CD86 surface markers. M1 activated macrophages have
enhanced phagocytosis, antigen presentation capability and tumoricidal activity. They
also secrete several pro-inflammatory cytokines such TNF-α, IL-6, IL-12 and IL-23 that
aid in the activation of effector cytotoxic T cells. Alternatively, in the presence of IL-4
and IL-13, macrophages get polarized to an ‘M2’ state with increasing levels of CD206
surface markers. M2 macrophages are usually associated with wound healing, immune
suppression, and anti-inflammatory responses. [18]
TAMs are often associated with worse prognosis. This is because cytokines present in the
tumor microenvironment activate macrophages into M2 state. These M2 TAMs support
angiogenesis, tumor cell metastasis and protect the tumor from immune response through
3

secretion of VEGF A, TGF β and through T-cell check point blockage which helps
cancers escape immune surveillance. (Fig 2) [19,20] They also secrete arginase 1 (ARG
1) that inhibit T cell activity by hydrolyzing L-arginine and converting it into urea and Lornithine. It is also implicated in angiogenesis and anti-inflammatory properties.

Figure 2: Anti-tumor and Pro-tumor functions associated with TAMs, Anfrey et al, 2019

1.3 Literature Survey
To utilize TAMs as an effective immunotherapy target, previous efforts have been
made to prevent recruitment of macrophage into the tumor through disruption of the
CCL2-CCL2 [21] receptor and CXCL12-CXCL receptor 4 axes. [22] While pre-clinical
studies found that this strategy helped eradicate tumor, discontinuing the treatment led to
rebounds. [23] Efforts have also been made to target and deplete M2 TAMs through use
of bisphosphonates such as zoledronate and clodronate. However, there is a strong
possibility that immune-protective cells are also targeted and eliminated, leading to
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severe repercussion such as bacterial infections. [24] FIG 3 summarizes the principal
strategies of utilizing TAMs for anti-cancer therapy.
Due to their plastic nature, macrophages can change their phenotype in response to
change in the microenvironment they are in. This has led to efforts in ‘re-educating’
TAMs from pro-tumoral M2 phenotype to anti-tumoral M1 phenotype through multiple
pathways such as CSF1/CSF1R blockage, TLR agonists, PI3Kγ and CD40 agonists.
Cancer cells secrete Macrophage Colony Stimulating Factor (MCSF) which binds to its
receptor CSF1R on macrophages. [25] This in turn activates a cascade of downstream
signaling resulting in their polarization to M2 phenotype. Blocking of the CSF1R can be
achieved through small molecules drugs such as BLZ945, PLX3397, ARRY 382 etc.
Blocking of CSF1R by BLZ945 has successfully resulted in repolarization of M2
macrophages into M1 type, leading to anti-tumor response and tumor regression. [26]
Therefore, targeted delivery of BLZ945 to M2 TAMs is an attractive avenue to pursue.
With many aggressive cancers, such as breast cancers, early detection of tumor
progression and metastasis becomes critical. Conventional imaging techniques such as
CT, PET and MRI lack the sensitivity required for this. [] Also, several patients
undergoing immunotherapy face severe side effects due to over-activation of the immune
system such as hepatic autoimmunity. [28] Every patient responds differently, making it
difficult to use standardized tests and imaging techniques. Therefore, there is a need for a
system that can accurately monitor early tumor response to therapy to differentiate
between responders and non-responders. Since M2 TAMs are heavily linked with
metastasis and overall poor prognosis, they can be used as diagnostic marker to predict
early stages of metastasis and to monitor patient response.
5

1.4 Research Objectives
I aim to design and evaluate a synthetic nanoparticle system that can deliver
therapeutic or diagnostic agents to M2 TAMs. To target TAMs with this system, I intend
to target the Scavenger Receptor B Class1 (SRB1) receptor, a murine multiligand
cholesterol receptor expressed on hepatic cells, smooth muscle cells, endothelial cells,
and macrophages as well. It promotes the uptake of cholesterol through High Density
Lipoprotein (HDL), a lipoprotein made by the liver. HDL consists mostly of
phospholipids, cholesterol and Apolipoproteins with a hydrophobic core encapsulating
triglycerides and esterified cholesterol. [29] The Apolipoprotein A1 is responsible for the
interaction of HDL with SRB1, leading to uptake of the cargo through a process called
selective lipid uptake in which only the encapsulated cargo is delivered. [30] This ability
of SRB1 to selectively uptake hydrophobic molecules, bypassing lysosomal degradation
makes it an attractive gateway for delivery of small molecules reconstituted in HDL
nanoparticles. []
Previously, SRB1 receptor has been targeted through synthetic or reconstituted HDL
nanoparticles in atherosclerosis and tumor disease models. [31, 32] Advantages of using
HDL nanoparticles include their relatively small size (~20nm), non-toxicity and
biodegradability. Human plasma derived Apo A1 has been used to synthesize HDL along
with phospholipids such as DPPC, DOPC etc., although recently several non-homologous
mimetic peptides have also been shown to target SRB1. [33] These nanoparticles have
been used to deliver anticancer drugs and imaging agents to tumors that overexpress
SRB1. However, very little research has been done towards using synthetic HDL
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particles to target and repolarize M2 TAMs in tumor models or in using them as
predictive markers for imaging.
In this project, I have designed an HDL nanoparticle system with the aim to deliver the
repolarizing agent BLZ-945 to M2 macrophages via the SRB1 receptor. (FIG 3)
Additionally, I have also used this system to deliver an arginase 1-responsive probe that
can differentiate between M1 and M2 macrophages. (Fig 4) The probe has a peptide
backbone to which a dye is attached. A quencher is attached to the arginine molecule in
the peptide backbone. Upon internalization, Arginase 1, produced only in M2
macrophages, is expected to cleave the bond between arginine and quencher, causing the
dye to fluoresce This will allow M2 macrophages to be selectively imaged.

Figure 3: Schematic to deliver CSF1R inhibiting drug to M2 macrophages
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Figure 4: Schematic for delivering Arginase responsive probe to M2 macrophages
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
Dichloromethane (DCM) and N, N-dimethylformamide (DMF) were purchased
from Fisher Scientific. 1,2 Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N- [amine (polyethylene glycol)-2000]
(ammonium salt) (DSPE-PEG amine 2000), cholesterol, and the mini handheld extruder
kit (including 0.4 μm and 0.2 μm Whatman Nucleopore Track-Etch Membrane,
Whatman filter supports, and 1 mL Hamiltonian syringes) were brought from Avanti
Polar Lipids. BLZ-945 drug was purchased from Selleck Chem. CD16/32 (Fc-block),
CD80, CD206 and SRB1 FACS antibodies were purchased from Biolegend Inc.
2.2 Methods
2.2.1 Peptide synthesis and Characterization
The R4F peptide Ac-FAEKFKEAVKDYFAKFWD was synthesized using the
AAPTEC Eclipse Peptide sequencer. The synthesized peptide was cleaved from the
peptide-resin by reacting it with Reagent K, a cleavage cocktail consisting of (v/v) 82.5%
TFA, 5% Phenol, 5% Thioanisole, 2.5% DODT and 5% water. The peptide was
precipitated out of the resultant solution by adding it to three times the volume of ice-cold
Di-ethyl Ether. The precipitate was collected upon centrifugation and further washed with
Diethyl Ether three more times. The precipitate was then lyophilized and characterized
using UltrafleXtreme MALDI-TOF/TOF in linear negative ion mode using α-cyano
matrix.

9

2.2.2 Nanoparticle Synthesis and Characterization
The nanoparticle is synthesized using the thin-film hydration method. Briefly, colipids taken in various molar ratios are dissolved in 1ml of DCM in a round bottom flask.
The solvent is then evaporated to form a thin film which is then rehydrated with R4F
peptide dissolved in PBS at 600C for 2 hours to form self-assembling nanoparticles. The
nanoparticle is extruded through 0.2 µm and 0.05 µm polycarbonate membrane using a
mini extruder. It is then passed through Sephadex G25 column. The hydrodynamic
diameter was measured by Dynamic Light Scattering (DLS) using Malvern Zetasizer
Nano ZSP (Malvern, UK). 10 μL of the nanoparticle solution was diluted into 1 mL using
Milli-Q water and 3 sets of 10 measurements were each performed at a 90-degree
scattering angle to get the mean particle size. Peptide and BLZ-945 loading are quantified
by measuring absorbance using UV-VIS spectrophotometer. Fluorescein Isothiocyanate
(FITC) and arginase responsive probe loading are quantified by measuring fluorescence
using microplate reader.
2.2.3 Flow Cytometry Protocol for SRB1 staining
RAW264.7 cells were seeded at a density of 2 x 105 cells per well in a 12 well
plate. The cells were incubated with 20ng/ml of IL4 for 24 hours to polarize them to M2
phenotype. Cells were then collected and permeabilized using Cytofix / Cytoperm (BD
biosciences) buffer as per manufacturer’s protocol. Cells were then stained with antiSRB1 antibody and analyzed using a Novocyte flow cytometer (Acea Biosciences) and
the results were processed using NovoExpress 1.2.5. The cells were gated for a live
population and isolated singlets to reduce autofluorescence from doublets
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2.2.4 Internalization
RAW264.7 macrophages were seeded at a density of 1.5 x 106 per well in 12 well
plates and were allowed to reach sub confluency. The cells were then stimulated with
20ng/ml of recombinant mouse IL-4 in DMEM media for 24 hours. Post that, the cells
were treated with 5uM of FITC loaded HDL nanoparticles at 1-, 4-, 8- and 24-hours’ time
points. Following treatment, the cells were washed with PBS and quantified using
Novocyte flow cytometer (Acea Biosciences) and the results were analyzed using
NovoExpress 1.2.5.
2.2.5 Repolarization
RAW264.7 macrophages were seeded at a density of 1.2 x 106 cells per well in 12
well plates. After reaching sub-confluency, the cells were polarized to M2 phenotype by
incubating them with 20nm/ml of IL-4 for 24 hours. They were then incubated with 1uM,
500nM and 100nM of BLZ945-chol or BLZ-chol loaded HDL nanoparticle for 48 hours.
After 48 hours, the cells were washed and stained with Pac Blue CD80 (M1 marker) and
quantified using Novocyte flow cytometer.
2.2.6 Microscopy
RAW264.7 cells were seeded at a density of 1 x 105 cells per well in an 8chamber slide and were allowed to reach sub confluency. They were then incubated for
24 hours with 20ng/ml of IL-4 or 100ng/ml LPS and 20ng/ml IFN-γ to polarize them into
M2 or M1 phenotype respectfully. They were then incubated with 1uM, 500nM and
100nM of arginase probe loaded HDL nanoparticle for 8 hours. The cells were then fixed
with 4% PFA and finally stained with DAPI. Images were taken with Nikon A1R-SIMe
confocal microscope and were analyzed using NIS Elements 4.6
11

CHAPTER 3
Synthesis and Optimization of HDL Nanoparticle
3.1 R4F Peptide Synthesis
The R4F peptide was synthesized using ECLIPSE peptide sequencer and
characterized using MALDI-TOF. It was found to have a molecular weight of 2315
g/mol, as was calculated theoretically. (FIG 5)

Figure 5: MALDI-TOF analysis of R4F

3.2 Synthesis of HDL Nanoparticle
HDL nanoparticle was synthesized using the thin film hydration method with
different molar concentration of R4F peptide as shown in Fig 6. It was seen that at lower
12

molar concentration of peptide, larger sized particles were formed. This could be because
the presence of peptide forms a nucleation site for the nanoparticle to form. Therefore,
higher amount of peptide led to formation of smaller nanoparticles. A minimum of 10
mol percent of R4F peptide was required to make nanoparticles of 18 nm – 25 nm. From
here on, further optimizations use 10 mol percent of R4F peptide.

Figure 6: Variation in Size due to changes in peptide composition

3.3 Optimization of Peptide Loading
Next, to maximize the peptide loading, the mol percent of DSPE-PEG amine 2000
was reduced. This is because DSPE-PEG is known to be integrated into the nanoparticle
in such a way that the PEG chains face outwards. So, reducing the content of DSPE-PEG
might provide more area for the peptide to interact. The loading of the peptide, as
measured by UV absorbance, was found to increase to some extent with decrease in
13

DSPE-PEG amine 2000. (Table 1) Further decrease caused instability in the HDL
nanoparticle. Hence, 10 mol percent of DSPE-PEG amine 2000 was used for further
experiments.
Table 1: Optimization of Peptide Loading

DSPE-PEG amine 2000
25
10
0

Peptide concentration
13%
40%
HDL nanoparticle not stable

3.4 Optimization for Stability
To increase the stability of the nanoparticle, different molar concentrations of
cholesterol were added. As seen in FIG 6, adding 1 percent of cholesterol did not prevent
increase in size. Increasing cholesterol content from 1 to 5% showed an increase in size
stability (FIG 7). Increasing the cholesterol content to 10% resulted in unstable
nanoparticle formation.

Figure 7: Changes in hydrodynamic diameter over three days in nanoparticles with different cholesterol compositions
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3.5 Optimization of Encapsulation Efficiency
Finally, the CSF1R inhibitor drug was added. (Fig 8) The encapsulation
efficiency was found to be 40%. Since the R4F peptide and BLZ-Chol have similar
wavelengths of absorption for UV, DCM-water mixture was used to separate the polar
and water-soluble peptide from the hydrophobic drug. The UV absorption of the
separated fractions were used to calculate loading. Increasing the amount of drug was
found to have no impact on the encapsulation efficiency. This could be because of the
relatively small size of the particle (~ 18 nm).

Figure 8: BLZ-Chol loaded HDL Nanoparticle with size ~ 18 nm
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Chapter 4
DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENT USING
HDL NANOPARTICLES
4.1 SRB1 Expression on M2 and M1 Polarized Macrophages
To study the expression of
SRB1 receptor on M2 and M1
polarized RAW264.7 macrophages,
they were permeabilized and stained
with anti-SRB1 antibody. 4T1 cancer
cells were used as a positive control, as
they are known to express SRB1.
While

permeabilizing

and

fixing

macrophages, it was seen that they
stuck together. This made it difficult to
gate for singlet population to rule out
autofluorescence. To counter this, the
acquiring

buffer

needed

to

be

Figure 9: SRB1 expression as percentage when compared to
positive control

optimized to include 1% EDTA to
prevent the cells from sticking together. It was seen that M2 polarized macrophages
express SRB1 significantly more than M1 polarized macrophages. Therefore, M2
macrophages can be selectively targeted through the SRB1 receptor. (FIG 9)

16

4.2 Internalization of HDL Nanoparticles in M2 polarized RAW264.7 Macrophages
FITC loaded nanoparticle was
used to study the internalization in M2
polarized

RAW264.7

macrophages.

The major concern here was the small
size

of

macrophages

nanoparticle.
are

known

While
to

indiscriminately phagocytose particles
over 100 nm in size, it has been shown
that particles smaller than 100nm are
not readily phagocytosed. [] While just

Figure 10: Internalization of FITC loaded HDL nanoparticle
over 24 hours

the nanoparticle without the targeting
peptide would have been the ideal control, we found that it was more than 150 nm in size.
This difference in size between the control and HDL nanoparticle might influence its
internalization, therefore free dye was used as control. The FITC loaded nanoparticles
were seen to be more readily internalized than the free dye control and maximum
internalization was observed at 8 hours’ time point (FIG 10).
4.3 Repolarization of M2 polarized RAW264.7 Macrophages by BLZ-Chol loaded
HDL Nanoparticle
BLZ-Chol loaded HDL nanoparticles were added to M2 polarized RAW264.7
macrophages to repolarize them to M1 phenotype. Free drug was used as control. Of the
three concentrations used, 1uM showed considerable increase in the expression of M1
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marker CD80. (FIG 11) The concentrations were calculated based on BLZ-Chol loading
in the HDL nanoparticles.

.
Figure 11: Repolarization of M2 RAW264.7 Macrophages with BLZ-Chol loaded HDL nanoparticles. Free BLZ-Chol was
used as control

4.4 Validation Assay with Arginase-Responsive Probe Loaded HDL Nanoparticle
Arginase responsive probe was loaded into the HDL nanoparticle with an encapsulation
efficiency of 30%. Upon testing it on M2 and M1 macrophages, it was found that, at
100nM concentration, only M2 macrophages show fluorescence. (Fig 12) At higher
concentrations, the system was found to be toxic to the cells.

18

Figure 12: Comparison of Probe fluorescence between M1 and M2 polarized Macrophages
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CHAPTER 5
DISCUSSION
In this project, an SRB1 targeting HDL nanoparticle system was designed to
deliver agents to M2 polarized macrophages. Several aspects of the nanoparticle, such as
size, peptide loading, and drug loading were optimized. After validating the expression
levels of SRB1 on macrophages, internalization studies showed that the nanoparticles get
internalized within 8 hours. It was then used to deliver CSF1R inhibitor drug BLZ-945, a
repolarizing agent, to M2 macrophages. An increase in M1 marker CD80 was seen after a
48-hour incubation period with 1uM of BLZ-Chol loaded HDL nanoparticle. This
increase was significantly more than compared to free drug. It was also used to deliver an
arginase-responsive probe to both M1 and M2 polarized macrophages. M2 macrophages
showed significantly high fluorescence as compared to M1 macrophages, even treated
with a concentration as low as 100nM. This shows that the system can effectively target
SRB1 expressing M2 macrophages. It can be used to target M2 like macrophages in
many disease models, particularly TAMs in tumors. Future work could be directed
towards validating the system in in-vivo tumor models for both therapeutic and
diagnostic purposes.
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